DiaSorin S.p.A.(DSRLF US)
$88.21+0.000.00%Ext:$89.14+0.931.05%(Market Closed · 20:00:00 UTC)
- Pricing and plans
Get the full experience
We save the real magic for signed-in users.
Established in 1968 and based in Saluggia, Italy, DiaSorin S.p.A. is a prominent player in the global diagnostics market. The company specializes in the creation, production, and distribution of sophisticated immunodiagnostic and molecular diagnostic testing kits. Its extensive reach spans across Europe, Africa, North, Central, and South America, the Asia Pacific region, and China. Among its offerings, DiaSorin provides a range of LIAISON platforms for immunodiagnostics, including the LIAISON XS, LIAISON XL, and LIAISON XL LAS systems. For molecular diagnostics, the LIAISON MDX platform is key, designed to amplify nucleic acids for identifying viruses in patient biological samples, thereby enabling the diagnosis of viral infections. DiaSorin also actively engages in strategic alliances to expand its diagnostic capabilities. These include a partnership with QIAGEN for a latent tuberculosis detection solution, a collaboration with TTP to develop molecular Point-of-Care solutions, and an agreement with MeMed to introduce a test that distinguishes between viral and bacterial infections.
Established in 1968 and based in Saluggia, Italy, DiaSorin S.p.A. is a prominent player in the global diagnostics market. The company specializes in the creation, production, and distribution of sophisticated immunodiagnostic and molecular diagnostic testing kits. Its extensive reach spans across Europe, Africa, North, Central, and South America, the Asia Pacific region, and China. Among its offerings, DiaSorin provides a range of LIAISON platforms for immunodiagnostics, including the LIAISON XS, LIAISON XL, and LIAISON XL LAS systems. For molecular diagnostics, the LIAISON MDX platform is key, designed to amplify nucleic acids for identifying viruses in patient biological samples, thereby enabling the diagnosis of viral infections. DiaSorin also actively engages in strategic alliances to expand its diagnostic capabilities. These include a partnership with QIAGEN for a latent tuberculosis detection solution, a collaboration with TTP to develop molecular Point-of-Care solutions, and an agreement with MeMed to introduce a test that distinguishes between viral and bacterial infections.